RT Journal Article SR Electronic T1 Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 6537 OP 6542 DO 10.21873/anticanres.13019 VO 38 IS 11 A1 HIROMICHI KAWAIDA A1 HIROSHI KONO A1 HIDETAKE AMEMIYA A1 RYOU SAITOU A1 ATSUSHI YAMAMOTO A1 NAOHIRO HOSOMURA A1 MITSUAKI WATANABE A1 AYAKO KIMURA A1 SHINJI FURUYA A1 HIROKI SHIMIZU A1 HIDENORI AKAIKE A1 YOSHIHIKO KAWAGUCHI A1 MAKOTO SUDO A1 JUN ITAKURA A1 HIROSHI HAYAKAWA A1 HIROKO SHINDO A1 EI TAKAHASHI A1 SHINICHI TAKANO A1 MITSUHARU FUKASAWA A1 SHINTARO ICHIKAWA A1 HIDEKI FUJII A1 DAISUKE ICHIKAWA YR 2018 UL http://ar.iiarjournals.org/content/38/11/6537.abstract AB Background/Aim: Nab-paclitaxel plus gemcitabine (nab-P+Gem) is one of most reliable and effective regimens for borderline or unresectable pancreatic cancer (PC). However, the feasibility and clinical benefits of this regimen have never been evaluated for patients with recurrent PC after pancreatectomy. The aim of this study was to investigate the feasibility of combination therapy with nab-paclitaxel plus gemcitabine (nab-P+Gem) for patients with recurrent PC. Patients and Methods: Twenty-two patients with recurrent PC received an intravenous infusion of nab-P (125 mg/m2) and Gem (1,000 mg/m2) on days 1, 8, and 15 of a 4-week cycle. The primary end-point of this study was completion of the 4 cycles. The secondary end-points were the safety, efficacy, and disease control rate. Results: The treatment completion rate of the 4 cycles was 90.9%. The objective response rate was 13.6% and the disease control rate was 63.6%. The median progression-free survival was 7.2 months. The most common grade 3 or higher hematological toxicity was neutropenia (72.7%). There was no treatment-related death. Furthermore, the chemotherapeutic effects varied with the time of recurrence. Conclusion: Combination nab-P+Gem therapy was well-tolerated and effective in patients with recurrent PC.